Bristol Myers Squibb Expands AI Partnership with Nvidia
Bristol Myers Squibb has announced an expanded collaboration with Nvidia to enhance its artificial intelligence capabilities in drug discovery and development. The pharmaceutical company is deploying a next-generation DGX SuperPOD supercomputer, aiming to build the most powerful AI factory in life sciences. This move follows Bristol Myers' ongoing efforts to leverage AI for faster and more cost-effective medicine development. Despite recent challenges such as patent exclusivity losses affecting revenue growth, Bristol Myers has been working on developing new drugs like milvexian and pumitamig to offset the impact of generic competition. The company's pipeline includes promising products that could drive future sales. Additionally, its stock is currently valued at a discount compared to healthcare sector averages. The article suggests that while AI may not immediately transform Bristol Myers' business, even modest improvements in efficiency from these technologies could have meaningful long-term benefits given the scale of their drug development programs.
Topics: Artificial Intelligence Drug Discovery Nvidia Partnership